glp 1 alzheimer Role of glucagon-like peptide-1 receptor agonists in Alzheimer's disease and Parkinson's disease | Journal of Biomedical Science GLP-1 Drug Fails to Quell
Description
Supports fat loss without restriction or burnout
As consumers continue to take their health and wellness goals seriously, GLP-1 drug usage will continue to grow.
The Trump administration announced agreements with Eli Lilly and Novo Nordisk to reduce the prices of the companies GLP-1 drugs.
A Sunlight survey found that GLP-1 users spend $218 less on groceries, fast food, snacks, dining out, and diet programs.
* Consult with HCP on appropriate management of your GLP-1 medication
Metseras pipeline includes MET-097i, a GLP-1 receptor agonist designed for once-monthly dosing, and MET-233i, an amylin analog being developed for monthly administration
